In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .
Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
AIM Cannabinoid receptor type 1 ( CB1 ) antagonists show central side effects , whereas beneficial effects are most likely peripherally mediated . In this study , the peripherally selective CB1 antagonist TM38837 was studied in humans . METHODS This was a double-blind , r and omized , placebo-controlled , crossover study . On occasions 1 - 4 , 24 healthy subjects received 5 × 4 mg THC with TM38837 100 mg , 500 mg or placebo , or placebos only . During occasion 5 , subjects received placebo TM38837 + THC with rimonabant 60 mg or placebo in parallel groups . Blood collection s and pharmacodynamic ( PD ) effects were assessed frequently . Pharmacokinetics ( PK ) and PD were quantified using population PK-PD modelling . RESULTS The TM38837 plasma concentration profile was relatively flat compared with rimonabant . TM38837 showed an estimated terminal half-life of 771 h. THC induced effects on VAS feeling high , body sway and heart rate were partly antagonized by rimonabant 60 mg [ -26.70 % [ 90 % confidence interval ( CI ) -40.9 , -12.6 % ] ; -7.10 % , ( 90%CI -18.1 , 5.3 % ) ; -7.30 % , ( 90 % CI -11.5 % , -3.0 % ) respectively ] and TM38837 500 mg [ -22.10 % ( 90 % CI -34.9 , -9.4 % ) ; -12.20 % ( 90 % CI -21.6 % , -1.7 % ) ; -8.90 % ( 90 % CI -12.8 % , -5.1 % ) respectively ] . TM38837 100 mg had no measurable feeling high or body sway effects and limited heart rate effects . CONCLUSIONS Rimonabant showed larger effects than TM38837 , but the heart rate effects were similar . TM38837 100 mg had no impact on CNS effects , suggesting that this dose does not penetrate the brain . This TM38837 dose is predicted to be at least equipotent to rimonabant with regard to metabolic disorders in rodent models . These results provide support for further development of TM38837 as a peripherally selective CB1 antagonist for indications such as metabolic disorders , with a reduced propensity for psychiatric side effects
In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .